ProfileGDS5678 / 1442730_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 64% 64% 62% 64% 67% 68% 64% 63% 63% 69% 63% 65% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9729766
GSM967853U87-EV human glioblastoma xenograft - Control 23.808164
GSM967854U87-EV human glioblastoma xenograft - Control 33.8442464
GSM967855U87-EV human glioblastoma xenograft - Control 43.692262
GSM967856U87-EV human glioblastoma xenograft - Control 53.8099964
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1337367
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1547968
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8087464
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7454463
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.766463
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2428969
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7156863
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9146665
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8224764